Physician profile
Yusra Mir
NPI 1932435757
$684.19
in general payments reported to CMS, 2019-2025
15 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.70 · 2020: $73.55 · 2021: $22.08 · 2022: $100 · 2023: $81.45 · 2024: $84.97 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $96.79 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $94.58 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $88.74 | 2025 | Shingrix |
| Novo Nordisk INC | $69.33 | 2019-2025 | Wegovy |
| Nevro Corp. | $67.94 | 2022 | |
| Amgen INC. | $61.62 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $42.09 | 2021-2023 | |
| Hologic Sales and Service, LLC | $26.82 | 2025 | Aptima |
| Merck Sharp & Dohme LLC | $26.28 | 2025 | Capvaxive, Gardasil 9, Enflonsia |
| Biowound Solutions, INC. | $22.82 | 2025 | Bio-Connekt |
| Phadia US INC. | $19.74 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.57 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.19 | 2020 | |
| Therapeuticsmd, INC. | $15.61 | 2019 | |
| Inspire Medical Systems, INC. | $15.07 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusra Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.